Literature DB >> 21498703

In silico/in vitro study of hybrid D-modified steroidal alkylator anticancer activity using uridine phosphorylase as target protein.

George D Geromichalos1, Elena Geromichalou, Charalambos Camoutsis, Michael Kontos, Panagiotis Dalezis, Athanasios Papageorgiou, Anastasios A Grivas, Christos Tsigris, Dimitrios T Trafalis.   

Abstract

BACKGROUND: In order to reduce toxicity and to enhance anticancer activity of nitrogen mustards, three hybrid steroidal esters were synthesized and tested in vitro against human pancreatic cancer cells expressing uridine phosphorylase (UPase). The inhibition potency against a target protein implicated in the chemotherapy of solid tumors, such as UPase, is of fundamental importance in the design and synthesis of new anticancer drugs.
MATERIALS AND METHODS: MTT colorimetric assay and molecular docking were employed for the in vitro and in silico drug evaluation, respectively.
RESULTS: A difference in cell sensitivity was found, which followed the known different UPase expression in the cell lines. Molecular docking studies on UPase protein, revealed the tested compounds to be bound to the binding cavity of the protein, with different affinity. Between the two D-modified compounds, the D-homo-aza (lactam)-hybrid compound (C2) was found to interact with the protein in a more efficient way.
CONCLUSION: The molecular docking data were in accordance with the in vitro results, where the lactam steroid alkylator showed significantly higher cytostatic and cytotoxic activity than the non-D-modified compounds, which also correlated with the level of UPase expression in the pancreatic cancer cells.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21498703

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  2 in total

1.  Identification of EPAC (Exchange Protein Activated by cAMP) bioinformatically as a potential signalling biomarker in Cardiovascular Disease (CVD) and its molecular docking by a lead molecule.

Authors:  Saranya Bala; Ravi Kant Pathak; Vachaspati Mishra
Journal:  Bioinformation       Date:  2011-05-26

2.  Azasteroid Alkylators as Dual Inhibitors of AKT and ERK Signaling for the Treatment of Ovarian Carcinoma.

Authors:  Panagiotis Dalezis; Eleni Geromichalou; Aikaterini Polonifi; Sofia Sagredou; Nikolaos Nikoleousakos; Michael Nikolaou; Vasiliki Sarli; Mihalis I Panayiotidis; Dimitrios T Trafalis
Journal:  Cancers (Basel)       Date:  2020-05-16       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.